Skip to content

Paul Summergrad

3 papers in the library · 623 citations · publishing 2016-2024

Papers

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders

JAMA Psychiatry March 1, 2017 Gerard Sanacora, Mark A. Frye, William M. Mcdonald et al. 577 citations

Ketamine can produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. However, existing studies have relatively small sample sizes, lack longer-term data on efficacy, and provide limited data on safety. Despite these limitations, ketamine is increasingly used off-label for mood and other psychiatric disorders. This review and consensus statement provides an overview of the data, highlights limitations, and offers suggestions to facilitate evidence-based clinical decision-making and patient safety.

DOI: 10.1001/jamapsychiatry.2017.0080 Ketamine Anxiety Mood disorders Medicine +4

Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement.

JAMA network open June 3, 2024 Amy L McGuire, I Glenn Cohen, Dominic Sisti et al. 41 citations

A consensus statement from a 2023 meeting of 27 experts identifies 20 points of consensus across five ethical issues for integrating psychedelic medicines into mainstream medical practice: reparations and reciprocity, equity, and respect; informed consent; professional boundaries and physical touch; personal experience; and gatekeeping. The meeting included clinicians, researchers, Indigenous groups, industry, philanthropy, veterans, retreat facilitators, training programs, and bioethicists. The statement focuses on government-approved medical use in the US and abroad, emphasizing that policymakers must address challenges ahead while acknowledging the hopeful moment.

DOI: 10.1001/jamanetworkopen.2024.14650 Full text Psychedelic therapy Psychedelic medicine Psychedelic treatment Psychedelics +15